跳至主要内容
临床试验/NCT05874141
NCT05874141已完成不适用

Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, Egypt

New Valley University2 个研究点 分布在 1 个国家目标入组 295 人开始时间: 2023年11月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
295
试验地点
2
主要终点
Number of participants with Liver disease

研究概览

简要总结

Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today

详细描述

All-cause mortality rates have declined substantially in several high-income countries, including England.

A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex.

Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially.

Many studies have primarily focused on identifying multimorbidity patterns in the general population.

The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with type 2 diabetes.

排除标准

  • Patients with type 1 diabetes.
  • Patients with secondary diabetes.

研究组 & 干预措施

type 2 DM

Other

干预措施: HBA1C (Diagnostic Test)

type 2 DM

Other

干预措施: Thyroid-stimulating hormone (Diagnostic Test)

type 2 DM

Other

干预措施: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides (Diagnostic Test)

type 2 DM

Other

干预措施: Urine analysis and urinary albumin-to-creatinine ratio (Diagnostic Test)

type 2 DM

Other

干预措施: Serum creatinine and estimated glomerular filtration rate (Diagnostic Test)

type 2 DM

Other

干预措施: Complete blood count (Diagnostic Test)

type 2 DM

Other

干预措施: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed (Diagnostic Test)

type 2 DM

Other

干预措施: Electrocardiography (ECG) (Procedure)

type 2 DM

Other

干预措施: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound (Procedure)

type 2 DM

Other

干预措施: Arterial duplex ultrasound of both lower limbs (Procedure)

type 2 DM

Other

干预措施: Random blood glucose (Diagnostic Test)

type 2 DM

Other

干预措施: AST, ALT, albumin (Diagnostic Test)

结局指标

主要结局

Number of participants with Liver disease

时间窗: At time of inclusion in the study

Number of participants with hypertension

时间窗: At time of inclusion in the study

Number of participants with thyroid disorder

时间窗: At time of inclusion in the study

Number of participants with Coronary heart disease

时间窗: At time of inclusion in the study

Number of participants with Infections

时间窗: At time of inclusion in the study

Number of participants with dyslipidemia

时间窗: At time of inclusion in the study

Number of participants with Diabetic kidney disease

时间窗: At time of inclusion in the study

Number of participants with Stroke

时间窗: At time of inclusion in the study

Number of participants with Peripheral arterial disease

时间窗: At time of inclusion in the study

Number of participants with Diabetic eye disease

时间窗: At time of inclusion in the study

Number of participants with Peripheral neuropathy

时间窗: At time of inclusion in the study

Number of participants with Cancer

时间窗: At time of inclusion in the study

次要结局

  • Number of participants with controlled diabetes mellitus with correlation to the number of cormobidity(At time of inclusion in the study)
  • Correlate the presence of each co-morbidity with the extent of diabetes control(At time of inclusion in the study)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Asmaa Nady Hussein

Lecturer of Internal Medicine and Clinical Hematology

New Valley University

研究点 (2)

Loading locations...

相似试验